Literature DB >> 16945675

The evolution of vesicoureteral reflux management in the era of dextranomer/hyaluronic acid copolymer: a pediatric health information system database study.

Thomas S Lendvay1, Mathew Sorensen, Charles A Cowan, Byron D Joyner, Michael M Mitchell, Richard W Grady.   

Abstract

PURPOSE: Since Food and Drug Administration approval of Deflux, injection therapy for vesicoureteral reflux has increased. Little data exist on the effect that injection therapy has had on the incidence of ureteral reimplantation and total vesicoureteral reflux procedures. We used the Pediatric Health Information System database to define practice trends for vesicoureteral reflux therapy.
MATERIALS AND METHODS: From 2002 to 2004 we extracted data on 0 to 19-year-old patients with International Classification of Diseases-9 diagnosis codes for vesicoureteral reflux, and procedure codes for ureteral reimplantation and subureteral injection therapy. Of 37 hospitals enrolled in Pediatric Health Information System 18 submitted ambulatory surgery and inpatient data. Data on the total number of patients who underwent reimplantation and injection were analyzed using linear regression analysis for trend.
RESULTS: We identified a total of 4,570 procedures performed in 1,948 patients treated with injection therapy and in 2,483 treated with reimplantation. The mean number of injections per institution yearly increased from 17 to 66 from 2002 to 2004 or 288%, while the mean number of reimplantations yearly was not statistically different from 2002 to 2004 (p = 0.02 and 0.09, respectively). In addition, the annual mean number of vesicoureteral reflux procedures per institution increased from 75 to 116 or 55% (p <0.05), primarily due to the increased number of injections.
CONCLUSIONS: With the introduction of a new, minimally invasive procedure for reflux therapy the number of procedures for reflux has increased, while open surgery rates have remained stable. This may be explained by public and clinician acceptance of a newer injection material that is safe and increasingly successful. To our knowledge this represents the largest series of patients treated for vesicoureteral reflux in the United States.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16945675     DOI: 10.1016/j.juro.2006.04.088

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

Review 1.  [Therapeutic options for primary vesicoureteral reflux: endoscopic vs open surgical approach].

Authors:  C Ziesel; S Frees; J W Thüroff; R Stein
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

2.  Cost-effectiveness of antimicrobial prophylaxis for children in the RIVUR trial.

Authors:  Lane S Palmer; Casey A Seideman; Yair Lotan
Journal:  World J Urol       Date:  2018-04-30       Impact factor: 4.226

3.  The accuracy and health risks of a voiding cystourethrogram after a febrile urinary tract infection.

Authors:  John David Spencer; Carlton M Bates; John D Mahan; Mary-Lynn Niland; Shannon R Staker; David S Hains; Andrew L Schwaderer
Journal:  J Pediatr Urol       Date:  2010-12-03       Impact factor: 1.830

4.  Injection volumes of dextranomer/hyaluronic acid are increasing in the endoscopic management of vesicoureteral reflux.

Authors:  Mathew D Sorensen; Martin A Koyle; Charles A Cowan; Ismael Zamilpa; Margarett Shnorhavorian; Thomas S Lendvay
Journal:  Pediatr Surg Int       Date:  2010-02-07       Impact factor: 1.827

Review 5.  Controversies Regarding Management of Vesico-ureteric Reflux.

Authors:  Ramesh Babu; Sujit Chowdhary
Journal:  Indian J Pediatr       Date:  2017-05-06       Impact factor: 1.967

6.  Readmissions, unplanned emergency room visits, and surgical retreatment rates after anti-reflux procedures.

Authors:  Hsin-Hsiao S Wang; Rohit Tejwani; Steven Wolf; John S Wiener; Jonathan C Routh
Journal:  J Pediatr Urol       Date:  2017-04-07       Impact factor: 1.830

7.  Contemporary Management of Vesicoureteral Reflux.

Authors:  Derrick L Johnston; Aslam H Qureshi; Rhys W Irvine; Dana W Giel; David S Hains
Journal:  Curr Treat Options Pediatr       Date:  2016-03-22

8.  Physician preference is a major factor in management of vesicoureteral reflux.

Authors:  Olivia T Lee; Blythe Durbin-Johnson; Eric A Kurzrock
Journal:  Pediatr Nephrol       Date:  2014-08-07       Impact factor: 3.714

9.  Is availability of endoscopy changing initial management of vesicoureteral reflux?

Authors:  Caleb P Nelson; Hillary L Copp; Julie Lai; Christopher S Saigal
Journal:  J Urol       Date:  2009-07-22       Impact factor: 7.450

Review 10.  Therapy for vesicoureteral reflux: antibiotic prophylaxis, urotherapy, open surgery, endoscopic injection, or observation?

Authors:  Jack S Elder
Journal:  Curr Urol Rep       Date:  2008-03       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.